Genfit’s (GNFT) Buy Rating Reiterated at HC Wainwright

Genfit (NASDAQ:GNFT)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $13.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 225.81% from the company’s current price.

Genfit Price Performance

Shares of GNFT stock opened at $3.99 on Friday. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit has a fifty-two week low of $3.35 and a fifty-two week high of $6.42. The stock’s 50-day moving average is $3.76 and its two-hundred day moving average is $4.43.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.